ELV 10-Q Quarterly Reports

Elevance Health, Inc. (ELV) reported its financial results for the third quarter and the first nine months of fiscal year 2025. The company demonstrated revenue growth driven by premium rate increases and expansion in its Medicare Advantage business, partially offset by Medicaid attrition. Net income saw an increase for the quarter, but a decrease for the nine-month period, influenced by factors such as investment performance, interest expenses, and tax impacts. Total assets grew to $122.8 billion from $116.9 billion at year-end 2024, with increases in current assets like premiums receivables and other receivables. Liabilities also increased, primarily due to higher medical claims payable and long-term debt. The company continues to manage its capital through dividends and share repurchases, while also investing in strategic acquisitions and business optimization initiatives. Regulatory changes and market dynamics, particularly in the healthcare landscape, remain key considerations for future performance.

Elevance Health, Inc. reported a decrease in net income for the three and six months ended June 30, 2025, compared to the prior year, primarily driven by increased benefit expenses and higher net losses on financial instruments. Despite the net income decline, total operating revenue saw a significant increase of 14.3% and 14.8% for the respective periods, driven by premium rate increases in the Health Benefits segment, recent acquisitions, and membership growth in Medicare Advantage and Individual ACA businesses. The company is actively managing its capital, evidenced by continued share repurchases and dividend payments, while also navigating evolving regulatory landscapes and integrating recent acquisitions. Key financial shifts include a substantial increase in benefit expenses due to higher medical cost trends, particularly in the Medicaid and Affordable Care Act (ACA) plans, which more than offset revenue growth in the Health Benefits segment. Conversely, the CarelonRx and Carelon Services segments demonstrated strong revenue and operating gain growth. The company maintained a solid liquidity position, with net cash provided by operating activities increasing year-over-year, supported by favorable working capital impacts.

Elevance Health, Inc. (ELV) reported its first-quarter 2025 financial results, demonstrating robust top-line growth driven by premium rate increases and membership gains in key segments like Medicare Advantage and Individual ACA. Total operating revenue increased by 15.4% year-over-year to $48.8 billion, while net income saw a slight decrease of 2.9% to $2.18 billion. This dip in net income was influenced by increased benefit expenses reflecting higher medical cost trends, and a rise in net losses on financial instruments. Despite these pressures, the company maintained its competitive position with a solid operating gain and a slight increase in diluted earnings per share to $9.61. The company continues to execute its strategic growth initiatives, including key acquisitions in the long-term care and home and community-based services sectors, reinforcing its diversified healthcare offerings.

Elevance Health, Inc. reported a net income of $1,008 million for the third quarter of 2024, a decrease from $1,300 million in the same period last year. Diluted earnings per share (EPS) were $4.36, down from $5.45 year-over-year. For the nine-month period, net income increased to $5,558 million from $5,160 million in 2023, with EPS rising to $23.81 from $21.56. Total operating revenue for the third quarter increased by 5.3% to $44,719 million, driven by premium rate increases and growth in CarelonRx. However, this was partially offset by a decline in Medicaid membership due to eligibility redeterminations. The company also incurred a $666 million accrual for the anticipated Provider Settlement Agreement related to the BCBSA litigation, impacting operating gain. Total assets grew to $116,533 million from $108,928 million at the end of 2023, supported by increased investments and property and equipment. The company continues to return capital to shareholders through dividends and share repurchases, with $11,111 million available for future repurchases. Elevance Health announced two pending acquisitions expected to close in late 2024 or early 2025, aimed at expanding its long-term care and home and community-based services.

Elevance Health, Inc. (ELV) reported its financial results for the second quarter and first half of 2024. For the quarter ended June 30, 2024, total revenues grew slightly to $43.9 billion from $43.7 billion in the prior year quarter. Shareholders' net income saw a significant increase of 24.1% to $2.3 billion, translating to diluted EPS of $9.85, up from $7.79 a year ago. This improvement was driven by better operating performance across all segments, a gain on the sale of its life and disability business, and increased net investment income, partially offset by higher income tax expense. The first six months of 2024 also showed positive trends, with total revenues increasing to $86.5 billion and shareholders' net income rising by 18.3% to $4.5 billion, resulting in diluted EPS of $19.44, up from $16.10 in the same period last year. The company highlighted strong growth in its CarelonRx and Carelon Services segments. However, total medical membership saw a decline of 4.6%, primarily due to Medicaid membership attrition following eligibility redeterminations, which the company expects to offset with growth in its commercial plans. Elevance Health completed the acquisition of Paragon Healthcare, Inc. in March 2024, further bolstering its CarelonRx segment. The company also announced an agreement to acquire Centers Plan for Healthy Living LLC, expected to close in the third quarter of 2024. The sale of its life and disability businesses in April 2024 contributed a $240 million gain. The company repurchased $1.03 billion of its common stock in the first half of 2024, demonstrating a commitment to returning capital to shareholders.

Elevance Health, Inc. reported solid financial results for the first quarter of 2024, demonstrating resilience and strategic execution in a dynamic healthcare landscape. Total revenues saw a modest increase of 1.0% to $42.6 billion, driven by premium rate adjustments and growth in its CarelonRx segment. Net income rose by a significant 12.2% to $2.25 billion, leading to a diluted Earnings Per Share (EPS) of $9.59, a 15.5% increase year-over-year. This performance was supported by improved operating gains across its Health Benefits, Carelon Services, and CarelonRx segments, coupled with a decrease in amortization of intangible assets and higher net investment income. Operationally, the company experienced a 3.9% decline in total medical membership, largely due to Medicaid redetermination effects and some attrition in employer group and Medicare segments. However, this was partially offset by growth in Individual, Employer Group fee-based, BlueCard, and FEHB memberships. Strategic acquisitions, such as Paragon Healthcare, Inc., and pending acquisitions like Centers Plan for Healthy Living LLC, underscore Elevance Health's commitment to expanding its care delivery capabilities and market reach. The company also announced the divestiture of its life and disability businesses, signaling a sharpened focus on its core health insurance and healthcare services operations.

Elevance Health, Inc. (ELV) reported its financial results for the third quarter and the first nine months of 2023. For the three months ending September 30, 2023, total revenues increased by 7.3% year-over-year to $42.85 billion, driven by higher premium revenues and growth in CarelonRx pharmacy revenue. However, net income saw a decline of 18.6% to $1.30 billion, primarily due to business optimization charges and increased net losses on financial instruments. The nine-month period showed a more positive trend in net income, which increased by 3.0% to $5.16 billion. Total operating revenue grew by 10.1% to $127.76 billion for the nine months. The company experienced a slight increase in total medical membership, with growth in Individual Public Exchange and Medicare Advantage products offsetting declines in Medicaid. Management is focused on efficiency programs and strategic acquisitions/divestitures, including the pending acquisition of Blue Cross Blue Shield of Louisiana. Key financial highlights include strong revenue growth, a slight increase in medical membership, and robust operating cash flow generation. However, the quarter was impacted by significant business optimization charges, leading to a year-over-year decrease in quarterly net income and EPS.

Elevance Health, Inc. (ELV) reported solid financial results for the quarter ending June 29, 2023, demonstrating continued growth and operational strength. Total revenues increased by 12.7% year-over-year for the quarter, driven by strong performance in its Health Benefits segment and growth in CarelonRx. Net income saw a healthy increase of 13.6% compared to the prior year's quarter, reflecting improved operating gains and efficient cost management. The company also reported a significant increase in operating cash flow, highlighting its ability to generate substantial cash from its core operations. Membership continued to grow, particularly in Medicaid and Medicare Advantage, underscoring the company's expanding reach in key government programs. Key strategic initiatives are progressing, including the pending acquisition of Blue Cross and Blue Shield of Louisiana, which is expected to further enhance the company's market position. Management highlighted prudent capital allocation, including ongoing share repurchases and dividend payments, reinforcing its commitment to shareholder value. Despite the dynamic healthcare landscape, Elevance Health has demonstrated resilience and strategic execution, positioning it favorably for future growth.

Elevance Health, Inc. (ELV) reported strong financial results for the quarter ending June 30, 2023. Total revenues increased by 13.0% year-over-year to $43.7 billion, driven by higher premium revenues in the Health Benefits segment and growth in CarelonRx. Net income saw a robust increase of 13.6% to $1.86 billion, or $7.79 per diluted share, up from $1.63 billion, or $6.73 per diluted share, in the prior year period. This performance was supported by operating gains across all segments, improved investment income, and a decrease in net losses on financial instruments. The company also experienced significant growth in medical membership, particularly in its Medicaid and Medicare Advantage offerings, contributing to the overall positive financial trajectory. Elevance Health continues to execute on its strategic initiatives, including brand portfolio reorganization and acquisitions, positioning itself for continued growth and value creation. The company's balance sheet remains strong, with total assets growing to $109.2 billion from $102.8 billion at the end of the previous year. Key drivers of this asset growth include increases in cash and cash equivalents, fixed maturity securities, and goodwill, reflecting business acquisitions. Liabilities also increased, primarily due to higher long-term debt and medical claims payable. Shareholders' equity strengthened, demonstrating the company's ability to generate and retain earnings. Operating cash flow for the six months ended June 30, 2023, was substantial at $8.4 billion, indicating healthy operational cash generation. Elevance Health also returned capital to shareholders through dividends and share repurchases, underscoring its commitment to shareholder value.

Elevance Health, Inc. (ELV) reported strong financial results for the first quarter of 2023, exceeding the previous year's performance. Total operating revenue increased by 10.6% to $41.9 billion, driven by robust membership growth across key segments including Medicaid, Medicare Advantage, and commercial fee-based plans. Net income saw a significant jump of 12.6% to $2.0 billion, translating to a diluted EPS of $8.30, up 13.4% year-over-year. This growth was supported by improved operating gains in its business segments, particularly Health Benefits and CarelonRx, alongside higher net investment income. The company also reported a substantial increase in operating cash flow, nearly tripling to $6.5 billion, bolstered by early premium receipts from CMS and positive working capital movements. Strategically, Elevance Health continues to evolve its brand portfolio and operational structure, with a new segment reporting alignment implemented in Q1 2023. The company also announced two significant M&A activities: the agreement to acquire Blue Cross Blue Shield of Louisiana and the pending sale of its life and disability businesses. These moves underscore Elevance Health's commitment to its long-term strategy of becoming a trusted health partner and expanding its integrated care solutions.

Elevance Health, Inc. (ELV) reported strong financial results for the third quarter and the first nine months of 2022, driven by significant revenue growth and a solid increase in net income. Total operating revenue surged by 11.5% year-over-year for the quarter and 14.9% for the nine-month period, primarily fueled by robust performance in the Government Business segment, notably Medicaid membership growth and acquisitions, as well as increased pharmacy product revenue from IngenioRx. Net income also saw a healthy increase, growing 7.4% for the quarter and 1.8% for the nine months. This growth was supported by improved operating gains across most segments, though partially offset by increased amortization expenses related to recent acquisitions and rebranding efforts. The company demonstrated effective management of medical cost trends and benefit expense ratios. With a significant increase in total medical membership, Elevance Health is well-positioned to continue its growth trajectory, leveraging its diversified business segments and strategic acquisitions.

Elevance Health, Inc. (ELV) reported strong revenue growth for the second quarter and first half of 2022, driven by increased membership, particularly in its Government Business segment (Medicaid and Medicare), and higher premium rates. Total operating revenue increased by 15.6% for the quarter and 16.8% year-to-date. Despite revenue growth, net income saw a slight decrease year-over-year, primarily attributed to losses on financial instruments compared to gains in the prior year, and increased amortization expenses related to acquisitions and rebranding efforts. The company successfully expanded its market reach, notably in the Individual and Government segments, and continued its strategic acquisitions, including Integra Managed Care. Elevance Health also recently rebranded, reflecting its evolution into a broader health partner. The company maintains a strong liquidity position and is actively managing its capital through share repurchases and dividends, indicating confidence in its ongoing operational performance and future prospects.

Elevance Health, Inc. (formerly Anthem, Inc.) reported a strong first quarter for 2022, with total revenues reaching $38.1 billion, an increase of 17.6% year-over-year. This growth was primarily driven by a significant increase in premium revenue, bolstered by organic membership growth in its Medicaid business, which benefited from the continued suspension of eligibility recertification due to the COVID-19 pandemic. The company also saw contributions from acquisitions and rate increases in its Medicare Advantage and Commercial risk-based businesses. Net income rose by 7.7% to $1.8 billion, leading to a diluted earnings per share (EPS) of $7.39, an increase of 10.1% compared to the prior year's quarter. The company also returned capital to shareholders through dividends and share repurchases, demonstrating a commitment to shareholder value while investing in growth. The company's robust performance was supported by strong membership growth, with total medical membership increasing by 7.5% to over 46.7 million. The Government Business segment, in particular, experienced substantial growth in Medicaid membership. This strategic expansion, coupled with operational efficiencies and favorable investment income, contributed to the positive financial results. Elevance Health also highlighted progress in its strategic initiatives, including its planned name change to Elevance Health, Inc. to better reflect its evolving business model, and ongoing acquisition activities aimed at expanding its capabilities in managed long-term care.

Elevance Health, Inc. (ELV) reported strong financial results for the third quarter and first nine months of 2021. Total operating revenue increased by 16.0% year-over-year for the quarter and 13.0% for the nine-month period, driven by significant membership growth, particularly in the Government Business segment (Medicare and Medicaid), and contributions from acquisitions like MMM Holdings. Net income saw a substantial increase of 576.6% for the quarter and 23.6% for the nine-month period, largely due to the absence of significant charges incurred in the prior year for business optimization initiatives and litigation accruals. Diluted earnings per share (EPS) also demonstrated robust growth, reflecting improved profitability and a reduction in outstanding shares due to ongoing share repurchase programs. The company's balance sheet remains strong, with increasing cash reserves and a manageable debt-to-capital ratio. Strategic acquisitions and organic membership growth are key drivers of the company's performance, positioning it well for continued expansion in the health benefits sector.

Elevance Health, Inc. (formerly Anthem, Inc.) reported strong revenue growth in the second quarter of 2021, with total revenues reaching $33.85 billion, an increase of 15.7% compared to the same period in 2020. This growth was primarily driven by a significant increase in premium revenues within the Government Business segment, fueled by membership gains in Medicaid and Medicare Advantage, and bolstered by higher pharmacy product revenue from the IngenioRx segment. Despite the revenue surge, net income saw a decrease of 20.9% to $1.80 billion, mainly attributed to rising benefit expenses related to the return of non-COVID-19 healthcare utilization to pre-pandemic levels and increased COVID-19 related costs, alongside lower operating gains in the Commercial & Specialty and Government segments. The company also completed two strategic acquisitions in the quarter: MMM Holdings, LLC and myNEXUS, Inc., which are expected to contribute to future growth and strategic alignment. The balance sheet shows a healthy increase in total assets to $96.10 billion, driven by significant increases in goodwill and other intangible assets resulting from these acquisitions. Debt levels also increased to support growth and operations. The company maintained a strong liquidity position, though operating cash flow saw a notable decrease compared to the prior year, primarily due to changes in working capital and tax payments. Overall, Elevance Health demonstrated robust top-line growth driven by its government business and PBM services, alongside strategic acquisitions. However, investors should note the pressure on profitability due to rising healthcare costs and the lingering impacts of the pandemic on utilization and expenses. The company's financial health remains solid, supported by its investment portfolio and strong liquidity.

Elevance Health, Inc. (formerly Anthem, Inc.) reported strong revenue growth in the first quarter of 2021, driven by increases in its Government Business segment, particularly Medicaid and Medicare Advantage, and its IngenioRx pharmacy benefits management segment. Total operating revenue rose by 9.0% year-over-year to $32.1 billion. Net income also saw a healthy increase of 9.5% to $1.67 billion, leading to a diluted Earnings Per Share (EPS) of $6.71, up 13.0% from the prior year. The company's balance sheet strengthened with cash and cash equivalents increasing significantly to $9.3 billion. Elevance Health also announced strategic acquisitions in the home-based care and Medicare Advantage sectors, signaling continued growth ambitions.

Elevance Health, Inc. (formerly Anthem, Inc.) reported its third quarter 2020 financial results, showing a notable increase in total revenues driven by higher premium revenue, particularly in its Government Business segment (Medicaid and Medicare), and the contribution from its IngenioRx pharmacy benefit management (PBM) business. Despite revenue growth, net income for the quarter saw a significant decrease compared to the prior year, primarily due to substantial charges related to business optimization initiatives and an accrual for the Blue Cross Blue Shield antitrust litigation. The company highlighted growth in its total medical membership, which increased by 4.0% year-over-year, fueled by Medicaid and Medicare expansion, partially offset by declines in fully-insured Local Group membership due to COVID-19 related unemployment. Financially, the company demonstrated strong operating cash flow. However, the report also details the impact of the COVID-19 pandemic, which has led to mixed effects on utilization and costs, with deferred elective procedures initially lowering claim costs but a rebound noted in the third quarter. The company also incurred additional COVID-19 related expenses. Management's focus remains on navigating these dynamic conditions, managing costs, and driving strategic growth, particularly through its PBM and integrated health services offerings.

Elevance Health, Inc. (formerly Anthem, Inc.) reported strong financial results for the second quarter ended June 30, 2020. Total operating revenue saw a significant increase of 15.9% year-over-year to $29.2 billion, driven by growth in premiums and the launch of its IngenioRx pharmacy benefit management (PBM) services. Net income more than doubled to $2.3 billion, or $8.91 per diluted share, reflecting improved operating gains across all segments and a temporary decrease in benefit expenses due to deferred healthcare utilization amid the COVID-19 pandemic. The company also maintained a solid balance sheet with total assets growing to nearly $88 billion and a healthy cash position. The company's strategic acquisition of Beacon Health Options, Inc. in February 2020 is expected to further diversify its business into health services. Despite the ongoing economic uncertainties related to COVID-19, Elevance Health demonstrated resilience, with management highlighting robust performance and a focus on adapting services for members and providers. Investors can take note of the strong revenue growth, substantial net income improvement, and strategic expansion into behavioral health as key takeaways from this report.

Elevance Health, Inc. (formerly Anthem, Inc.) reported its first-quarter 2020 financial results, showing resilience despite the emerging COVID-19 pandemic. Total operating revenue increased by 20.7% to $29.4 billion, largely driven by the launch of its Pharmacy Benefit Manager (PBM) subsidiary, IngenioRx, and higher premium revenues from rate increases and membership growth in its Government Business segment. Net income saw a slight decrease of 1.8% to $1.5 billion, or $5.94 per diluted share, impacted by higher income tax expense due to the reinstatement of the Health Insurance Provider (HIP) Fee and net realized losses on financial instruments. The company completed the acquisition of Beacon Health Options, Inc., a significant move to diversify into behavioral health services. While facing economic uncertainties and potential impacts from COVID-19 on healthcare costs and membership, Elevance Health demonstrated strong operating cash flow growth and maintained a robust financial position. The company also highlighted its proactive measures to support members and employees during the pandemic, including waiving cost-sharing for telehealth and COVID-19 treatments, and temporarily suspending its share repurchase program.

Elevance Health, Inc. (ELV), formerly Anthem Inc., reported strong financial results for the nine months ended September 30, 2019. Total operating revenue increased by 11.7% year-over-year to $76.0 billion, driven by robust growth in premiums, particularly within the Government Business segment (Medicaid and Medicare), and increased administrative fees and other revenue, bolstered by the new IngenioRx pharmacy benefit manager. Net income saw a significant increase of 16.5% to $3.87 billion, leading to a diluted EPS of $14.83, up from $12.58 in the prior year period. This performance was supported by improved operating results across key segments and a lower effective tax rate, partly due to the suspension of the Health Insurance Provider (HIP) Fee for 2019. The company also maintained a solid operating cash flow of $4.73 billion, indicating strong operational cash generation. Elevance Health continues to expand its membership, with total medical membership growing by 2.7% to over 41 million, primarily in its fully-insured Medicaid and Medicare offerings.

Elevance Health, Inc. (ELV) reported a solid financial performance for the quarter ending June 30, 2019. Total operating revenue saw a significant increase of 10.8% year-over-year, reaching $25.18 billion. This growth was primarily driven by higher premium revenues, reflecting both membership increases and strategic rate adjustments across its Government Business and Commercial & Specialty Business segments. Net income also showed a healthy increase of 8.1% to $1.14 billion, supported by improved operational performance and a substantial reduction in income tax expense due to the suspension of the Health Insurance Provider (HIP) Fee. The company's membership base continued to expand, with total medical membership growing by 3.3% year-over-year. This growth was particularly strong in the Government Business segment, driven by Medicaid and Medicare programs. Elevance Health also announced a significant strategic move with the agreement to acquire Beacon Health Options, Inc., a major behavioral health organization, signaling a continued focus on expanding its health services capabilities. Overall, the results demonstrate Elevance Health's ability to drive revenue growth, manage costs effectively, and expand its market reach. The company's strategic initiatives, including the anticipated acquisition and its PBM services through IngenioRx, position it for continued expansion and value creation for its shareholders. Investors should monitor the integration of Beacon Health Options and the ongoing performance of its key business segments, particularly the Government Business, which showed robust growth.

Elevance Health (ELV), formerly Anthem, Inc., reported a strong first quarter for 2019, with total operating revenue increasing by 9.2% to $24.4 billion compared to the prior year's period. This growth was primarily driven by higher premium revenues in both the Government and Commercial & Specialty businesses, fueled by membership increases and strategic rate adjustments. Net income saw a significant jump of 18.2% to $1.55 billion, resulting in diluted earnings per share of $5.91, up from $4.99 in the same period last year. The company also benefited from the suspension of the Health Insurance Provider (HIP) Fee in 2019, which positively impacted net income and the effective tax rate. Despite a decrease in operating cash flow due to timing differences in Medicare prepayments and the HIP Fee suspension's impact on premium receipts, Elevance Health maintained a robust financial position. The company continued its capital return program through share repurchases and dividend payments, reflecting confidence in its ongoing operational performance and future outlook. Key strategic initiatives, such as the development of its PBM IngenioRx and the integration of the America's 1st Choice acquisition, are progressing, positioning the company for continued growth and market leadership in the healthcare sector.

Elevance Health, Inc. (formerly Anthem, Inc.) reported solid financial results for the nine months ended September 30, 2018. Total operating revenue increased by 2.1% to $68,037 million, driven by higher premium revenue, particularly in the Government Business segment, and increased administrative fees in the Commercial & Specialty Business segment. Net income saw a significant increase of 27.3% to $3,325 million. This growth was primarily attributed to improved operating results in both major business segments, bolstered by the positive impact of acquisitions in the Medicare Advantage space and a lower effective tax rate following the Tax Cuts and Jobs Act. Diluted earnings per share also rose substantially by 29.7% year-over-year. Despite an overall increase in revenue and net income, operating cash flow for the nine months decreased by $2,122 million compared to the prior year. This decline was attributed to factors including lower cash receipts from ACA premium stabilization programs, increased investments in growth initiatives, and membership declines in certain segments. The company continues to actively manage its capital through share repurchases and dividend payments, demonstrating a commitment to shareholder returns while navigating a complex regulatory and market environment.

Elevance Health, Inc. (ELV) reported strong financial performance for the period ending June 30, 2018. Total operating revenue increased by 2.3% to $22.7 billion for the quarter and 1.2% to $45.1 billion for the first six months of the year, driven by higher premium revenue in the Government Business segment and increased administrative fees. Net income saw a significant increase of 23.2% to $1.05 billion for the quarter and 26.8% to $2.37 billion for the first six months. Diluted EPS also rose substantially by 25.9% and 30.2% respectively for the same periods. The company experienced a decrease in overall medical membership by 2.2% to approximately 39.5 million members, primarily due to reduced participation in ACA-compliant marketplaces and declines in fully-insured and Medicaid businesses. However, Medicare membership grew by 17.1%, boosted by acquisitions and organic growth. The company also announced the establishment of a new PBM, IngenioRx, in partnership with CVS Health, set to begin operations in 2020. Financially, the company maintained a solid position with $24.7 billion in cash, cash equivalents, and investments. Operating cash flow was $2.76 billion for the six months ended June 30, 2018. Elevance Health continued its capital return program through share repurchases and dividend payments, reflecting confidence in its ongoing financial health and strategic initiatives.

Elevance Health, Inc. (ELV) reported solid financial performance for the first quarter of 2018, with total revenues of $22.54 billion, a slight increase of 0.1% year-over-year. Net income saw a significant jump of 30.0% to $1.31 billion, leading to diluted earnings per share (EPS) of $4.99, up 33.8% from the prior year's first quarter. This strong profit growth was driven by higher operating results in both the Commercial & Specialty Business and Government Business segments, alongside a notable decrease in income tax expense, largely attributable to the Tax Cuts and Jobs Act of 2017 which lowered the federal corporate tax rate. Total medical membership slightly declined by 2.5% to 39.6 million, primarily due to reduced participation in ACA-compliant marketplaces and Medicaid business, though this was partially offset by growth in Medicare. The company's financial position remained robust, with total assets growing to $73.30 billion and total liabilities increasing to $46.29 billion, resulting in total shareholders' equity of $27.01 billion. Key financial activities during the quarter included strategic acquisitions within the Government Business segment, the repayment of debt, and continued share repurchases and dividend payments to shareholders. Despite a decrease in operating cash flow compared to the previous year, the company maintained sufficient liquidity and a stable debt-to-capital ratio. Investors should note the ongoing litigation and regulatory scrutiny, particularly concerning the Express Scripts PBM agreement and past data security incidents, which continue to present potential risks.

Elevance Health, Inc. (formerly Anthem, Inc.) reported solid financial results for the third quarter and first nine months of 2017. Total operating revenue saw a notable increase, driven by higher premium revenues in both the Government and Commercial & Specialty Business segments. Net income also showed significant year-over-year growth, attributed to lower income tax expenses (largely due to the suspension of the Health Insurance Provider Fee) and improved investment income. The company continued to focus on strategic growth, announcing two acquisitions in the Medicare Advantage space: HealthSun Health Plans, Inc. and America's 1st Choice. These align with Elevance Health's strategy to expand its presence in these key markets. Despite some headwinds, such as a decrease in operating gain for the Commercial & Specialty Business segment, the overall financial performance and robust operating cash flow indicate a company managing its operations effectively while pursuing strategic expansion.

Elevance Health, Inc. (formerly Anthem, Inc.) reported solid financial performance for the six months ended June 30, 2017. Total operating revenue increased by 7.1% year-over-year to $44.5 billion, driven by higher premium revenues across both Government and Commercial & Specialty segments. Net income saw a significant jump of 25.7% to $1.9 billion, largely attributed to lower income tax expenses, notably the suspension of the Health Insurance Provider Fee (HIP Fee) and favorable tax benefits from prior acquisition costs. Diluted EPS also grew by 24.4% to $6.89. The company experienced growth in its medical membership by 1.6%, reaching over 40.3 million members, with notable increases in Medicaid and Local Group segments. However, operating gain for the segments saw a decline, particularly in the Government Business (down 21.1%) and Commercial & Specialty Business (down 4.1%), driven by factors such as the HIP Fee suspension and increased incentive compensation. Despite these segment-level pressures, the overall financial health appears robust, supported by strong operating cash flow of $3.1 billion. Investors should monitor the ongoing legal proceedings, particularly the litigation with Cigna and the ongoing pharmacy benefit management dispute with Express Scripts, which represent significant contingent liabilities and potential financial risks.

Elevance Health, Inc. (formerly Anthem, Inc.) reported strong financial performance for the first quarter of 2017, with operating revenue increasing by 9.9% year-over-year to $22.3 billion and net income rising by 43.7% to $1.01 billion. This growth was driven by higher premium revenues across its commercial and government segments, reflecting rate increases and membership expansion, particularly in Medicaid and Local Group offerings. The company also benefited from a suspension of the Health Insurance Provider (HIP) Fee for 2017, which reduced expenses and income tax obligations. Despite robust revenue and net income growth, investors should note the ongoing significant legal and regulatory challenges. The company is heavily involved in litigation concerning its proposed acquisition of Cigna Corporation, with a pending appellate decision after a district court ruled against the merger. Additionally, Anthem is facing other substantial legal actions, including a major antitrust lawsuit involving Blue Cross Blue Shield licensees and a significant lawsuit against its pharmacy benefit manager, Express Scripts, over pricing disputes. While the company reported increased operating cash flow and a solid liquidity position, these ongoing legal matters and the inherent complexities of the healthcare industry present notable risks to future performance.

Elevance Health, Inc. (ELV) reported solid revenue growth for the nine months ended September 30, 2016, with total operating revenue increasing by 7.4% year-over-year to $62.7 billion. This growth was primarily driven by higher premium revenues, particularly in the Government Business segment, and increased administrative fees. However, net income saw a decline of 11.7% for the same period, reaching $2.1 billion. This decrease was influenced by higher benefit expenses due to increased medical costs and membership growth, as well as costs associated with the pending acquisition of Cigna Corporation and increased interest expenses. The company also experienced a decrease in net income for the third quarter of 2016 compared to the prior year, reflecting similar pressures from rising benefit expenses and acquisition-related costs. Despite the dip in net income, the company's medical membership grew by 3.1% year-over-year, driven by strong performance in Medicaid and National Accounts. Investors should note the ongoing regulatory scrutiny and litigation surrounding the proposed Cigna acquisition, which could impact future strategic decisions and financial performance.

Elevance Health, Inc. (formerly Anthem, Inc.) reported its financial results for the quarter and six months ended June 30, 2016. The company experienced revenue growth driven by higher premium revenue in its Government Business segment and increased administrative fees in its Commercial and Specialty Business segment. However, net income and diluted earnings per share decreased compared to the prior year period. This decline was primarily attributed to higher benefit expenses due to increased medical costs and membership growth, especially in the Medicaid segment, as well as lower net realized gains on financial instruments and costs associated with the pending acquisition of Cigna Corporation. Despite the decrease in profitability, Elevance Health maintained a strong financial position with significant cash and investments. The company continued to manage its operations across its Commercial and Specialty, Government, and Other segments, with the Government Business segment showing robust revenue growth, though its operating gain declined. Investors should note the ongoing strategic initiatives, including the significant pending acquisition of Cigna, which is facing antitrust scrutiny, and the ongoing management of medical cost trends.

Elevance Health, Inc. (ELV) reported its first quarter 2016 financial results, showing a solid increase in total operating revenue, driven by higher premium revenues in its Government Business segment and increased administrative fees. While revenue growth was positive, the company experienced a decline in net income and diluted earnings per share compared to the prior year's quarter. This decrease was primarily attributed to higher investment-related losses, increased interest expenses, and costs associated with the pending acquisition of Cigna. The company's medical membership grew by 2.8%, reaching 39.6 million, with notable increases in National Accounts and Medicaid segments. Despite the revenue growth and membership expansion, investors should note the impact of increased benefit expenses and the ongoing integration costs and financial implications of the proposed Cigna acquisition, which is expected to close in the second half of 2016. The company also highlighted ongoing litigation and the lingering effects of a significant cyber attack in February 2015, though contingency plans and insurance are in place.

Elevance Health, Inc. (ELV) reported its third-quarter 2015 financial results, showing robust top-line growth and a notable increase in net income. Total operating revenue for the quarter reached $19.8 billion, a 7.6% increase year-over-year, driven by higher premium revenues, particularly in the Government Business segment, and increased administrative fees. Net income rose by 3.8% to $654.8 million, or $2.43 per diluted share, up from $2.22 in the prior year's comparable period. This earnings per share (EPS) growth was supported by both increased net income and a reduction in outstanding shares. The company also highlighted significant progress in its strategic initiatives, including the acquisition of Simply Healthcare and the announcement of its pending merger with Cigna Corporation, which is expected to significantly scale the business. Despite a notable cyber attack in early 2015, the company's operational and financial performance remained strong, demonstrating resilience. Investors should note the continued growth in membership, particularly in government programs, and the company's effective management of cost trends.

Elevance Health, Inc. (ELV) reported strong financial performance for the six months ended June 30, 2015. Total operating revenue increased by 7.6% year-over-year to $38.6 billion, driven by higher premium revenue in the Government Business segment and increased administrative fees. Net income saw a significant increase of 20.4% to $1.72 billion, or $6.22 per diluted share, reflecting improved operating results across both commercial and government segments and higher net realized investment gains. The company also demonstrated robust operating cash flow, increasing by $365 million to $2.82 billion, primarily due to premium receipts and membership growth. Notably, Elevance Health announced a significant subsequent event: an Agreement and Plan of Merger with Cigna Corporation, valued at approximately $53 billion. This acquisition, expected to close in the second half of 2016, aims to create a premier health benefits company. The company also completed the acquisition of Simply Healthcare in February 2015, strengthening its position in the government sector. Despite these strategic moves, the company also disclosed a cyber attack in February 2015, the full impact of which is still being assessed, and ongoing legal proceedings, including antitrust litigation.

Elevance Health, Inc. (ELV) reported robust financial performance for the first quarter of 2015, with total operating revenue reaching $18.9 billion, a 6.8% increase year-over-year. This growth was primarily driven by a significant rise in premium revenue within its Government Business segment, bolstered by increased membership in Medicaid and the recent acquisition of Simply Healthcare. Net income also saw a substantial increase of 23.4% to $865.2 million, translating to a diluted EPS of $3.09, up from $2.40 in the prior year quarter. This EPS growth was further supported by an effective share repurchase program. The company demonstrated strong operational cash flow generation of $1.65 billion, a 19% increase from the prior year, reflecting improved premium receipts and membership growth. Strategically, Elevance Health completed the acquisition of Simply Healthcare, strengthening its position in the government sector, and continued to manage its capital effectively through share repurchases and dividend payments. Despite a sophisticated cyber attack in February 2015, the company reported no material impact on its financial condition or results of operations from this incident to date, though ongoing expenses are anticipated.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported a solid third quarter and first nine months of 2014, demonstrating revenue growth driven by increased premium revenue in its Government Business segment and higher administrative fees in its Commercial and Specialty Business segment. Despite a slight year-over-year decrease in net income for the quarter, primarily due to the impact of the new Health Insurance Provider (HIP) Fee and lower investment income, the company's diluted Earnings Per Share (EPS) saw a modest increase due to effective share repurchase programs. The company's balance sheet reflects steady growth in total assets, supported by strong performance in investments and receivables. Liabilities also saw an increase, largely driven by policy liabilities and long-term debt, reflecting the company's strategic financial management. Significant focus was placed on managing capital through substantial share repurchases and dividend payments, underscoring a commitment to shareholder returns. The company also highlighted its strategic positioning within the evolving healthcare landscape, including the upcoming name change to Anthem, Inc., and its continued adaptation to the Affordable Care Act. Overall, Elevance Health presented a picture of financial resilience and strategic adaptation. Investors can note the consistent revenue growth, effective capital management strategies, and the company's proactive approach to navigating regulatory changes and market dynamics. While challenges such as the impact of the HIP Fee and specific segment pressures exist, the overall trajectory indicates a stable and growing enterprise.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported solid revenue growth for the first half of 2014, with operating revenue increasing by 4.2% for the quarter and 2.7% year-to-date, driven by strong performance in its Government Business segment, particularly Medicaid, and increased administrative fees in its Commercial and Specialty Business segment. However, net income for the quarter and year-to-date periods saw a decline, primarily attributed to the impact of new, non-tax-deductible fees associated with the Patient Protection and Affordable Care Act (ACA) and ongoing costs related to market changes. Despite the dip in net income, the company demonstrated robust operating cash flow generation, significantly increasing by 1.7 times net income for the six-month period compared to the prior year, signaling strong operational liquidity. The company continued its commitment to shareholder returns through substantial share repurchases and dividend payments.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported its first quarter 2014 financial results, showing a slight increase in total operating revenue to $17.64 billion, up 1.2% year-over-year, driven by growth in its Government Business segment, particularly Medicaid, and increases in premium rates across various segments. However, net income saw a notable decrease of 20.8% to $701 million, resulting in diluted earnings per share (EPS) of $2.40, down from $2.89 in the prior year. The decline in profitability was primarily attributed to increased costs associated with healthcare reform, including the new non-tax deductible Health Insurance Provider Fee (HIP Fee), and shifts in product mix within the Commercial and Specialty Business segment. Despite the profitability dip, the company demonstrated strong operating cash flow of $1.39 billion, a significant increase from the prior year, indicating robust cash generation from its core operations. Management highlighted a strategic focus on its core Commercial and Specialty and Government Business segments, evidenced by the divestiture of its 1-800 CONTACTS business in January 2014.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported a mixed financial performance for the nine months ended September 30, 2013. Total operating revenue saw a significant increase of 16.3% to $52.9 billion, driven by higher premium revenues, particularly from the acquisition of Amerigroup and growth in government business segments. However, net income for the same period decreased slightly by 5.1% to $656.2 million for the third quarter, attributed to increased project costs related to healthcare reform implementation and losses on debt extinguishment, despite improved operating results in government business and lower income tax expenses. Despite the slight dip in quarterly net income, diluted Earnings Per Share (EPS) showed a positive trend, increasing by 16.0% for the nine-month period to $7.69, largely due to share repurchase activities reducing outstanding shares. The company also demonstrated strong operating cash flow, increasing by approximately $795 million year-over-year, signaling robust operational performance and financial health. The company's balance sheet remains substantial with over $60 billion in total assets, though it is managing a significant debt load, with a debt-to-capital ratio slightly above its target range.

Elevance Health (formerly WellPoint) reported a strong second quarter of 2013, demonstrating significant revenue growth and improved net income compared to the prior year. Total operating revenue increased by 16.0% to $17.6 billion, primarily driven by the acquisition of Amerigroup and premium rate increases in its Government and Commercial businesses. Net income saw a substantial increase of 24.3% to $800.1 million, resulting in a diluted EPS of $2.64, up from $1.94 in the prior year period. This growth was fueled by higher operating results across both government and commercial segments, despite increased interest expenses related to the Amerigroup acquisition. The company continues to manage its capital effectively through share repurchases and dividend payments, indicating a focus on shareholder returns while investing in growth. Key financial strengths include a robust operating revenue increase supported by strategic acquisitions and pricing adjustments. The company also managed to improve its net income and EPS, showcasing operational efficiency. Despite a decrease in net investment income, the overall financial performance highlights the company's resilience and ability to navigate market dynamics. Investors can take comfort in the positive growth trajectory and the company's commitment to shareholder value, though ongoing integration costs and market pressures remain factors to monitor.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported solid financial performance for the first quarter ended March 31, 2013. Total revenues grew by 14.7% to $17.7 billion, driven by a significant increase in operating revenue, largely attributable to the acquisition of Amerigroup in December 2012, alongside organic growth in premium revenue. Net income saw a modest increase of 3.4% to $885.2 million, resulting in diluted earnings per share (EPS) of $2.89, a 14.2% increase year-over-year. This EPS growth was bolstered by a reduction in outstanding shares due to the company's active share repurchase program. Operational highlights include strong growth in the Consumer segment, largely fueled by the Amerigroup acquisition, while the Commercial segment experienced a slight revenue dip due to strategic product adjustments and market pressures. The company maintained a solid benefit expense ratio and demonstrated improved efficiency with a lower selling, general, and administrative expense ratio. Despite a decrease in operating cash flow compared to the prior year, primarily due to timing of government payments, the company's liquidity remains strong, supported by significant cash and investments. Investors should note the company's continued focus on capital allocation through dividends and share repurchases, as well as ongoing efforts to manage healthcare cost trends.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported its third-quarter 2012 financial results, showing a slight increase in net income to $691.2 million ($2.15 per diluted share) from $683.2 million ($1.90 per diluted share) in the prior year's quarter. While total operating revenue remained largely flat year-over-year at $15.13 billion, driven by a slight decrease in premium revenue offset by growth in other revenue streams including the recent acquisition of 1-800 CONTACTS, the company saw improvements in its Commercial segment's operating gain. Despite a decrease in overall medical membership by 2.5%, strategic growth was observed in Senior and State-Sponsored segments. The company is in the process of a significant pending acquisition of Amerigroup Corporation, expected to close in the fourth quarter of 2012, which is anticipated to bolster its capabilities in serving the Medicaid population. WellPoint also highlighted its ongoing commitment to capital return through share repurchases and dividends, though the company's debt-to-capital ratio increased to 36.3% from 29.6% due to increased debt financing for the Amerigroup acquisition.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported its financial results for the second quarter and first half of 2012. For the second quarter, total revenues increased by 2.0% to $15.4 billion, while net income decreased by 8.3% to $643.6 million. This decrease was primarily attributed to higher litigation settlement costs, which were non-tax deductible, leading to increased general and administrative expenses and income tax expense. Diluted EPS saw a slight increase to $1.94, benefiting from a lower share count due to share repurchases. For the first half of 2012, total revenues grew by 2.8% to $30.8 billion, with net income declining by 7.9% to $1.5 billion. Similar to the quarterly results, the year-to-date decline in net income was driven by the non-tax deductible litigation settlement costs and lower operating results in the Commercial segment, partly offset by improvements in the Consumer segment. Diluted EPS for the first half increased to $4.48. The company also announced its intent to acquire Amerigroup Corporation for approximately $4.9 billion, a significant strategic move to expand its reach in serving vulnerable populations.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported its first-quarter 2012 financial results, showcasing a 3.4% increase in total operating revenue to $15.15 billion, primarily driven by growth in its Consumer segment, particularly Medicare Advantage, and higher premium rates in its Commercial segment. Despite revenue growth, net income saw a 7.6% decrease to $856.5 million compared to the prior year, attributed to decreased operating results in the Commercial and Other segments, partly offset by improved Consumer segment performance and lower income taxes. Diluted Earnings Per Share (EPS) increased slightly by 3.7% to $2.53, benefiting from a reduced share count due to ongoing share repurchase programs. The company experienced a slight overall decline in medical membership by 1.5%, with decreases in Local Group and National Accounts offset by growth in Senior and State-Sponsored segments. Cost of care trends remained a key focus, with an estimated medical cost trend of 7.0% for the rolling twelve months ended March 31, 2012. Management highlighted ongoing efforts in cost management, provider contracting, and value-based care initiatives. The company maintained a strong liquidity position, with $21 billion in cash, cash equivalents, and investments, and a consolidated debt-to-capital ratio of 28.7%.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported its third-quarter results for the period ending September 30, 2011. The company experienced a slight increase in total operating revenue, driven by premium rate adjustments and membership growth in specific segments, particularly its Senior business. However, net income saw a decrease compared to the prior year quarter, primarily due to lower operating results in the Commercial and Consumer segments. Despite this, diluted Earnings Per Share (EPS) showed a modest increase, largely attributed to a reduced number of outstanding shares resulting from ongoing share repurchase programs. The company also completed a significant acquisition, CareMore Health Group, Inc., which is expected to bolster its offerings in the senior market. Management highlighted strategic initiatives focused on enhancing healthcare value and improving health outcomes, particularly for seniors. The report also detailed ongoing litigation and risk factors, which are common for large health insurers. Investors should note the company's continued commitment to capital return through share buybacks and dividends, balanced with strategic investments and debt management.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported solid revenue growth for the first six months of 2011, with total operating revenue increasing by 2% to $29.53 billion compared to the same period in 2010. This growth was primarily driven by premium rate increases and a rise in membership across various segments, particularly in national accounts, BlueCard, and senior plans. The company also saw an increase in net income to $1.63 billion, representing a 2% rise year-over-year, driven by improved operating results in the Commercial and Other segments, along with lower income taxes. Diluted Earnings Per Share (EPS) also saw a significant increase of 18% to $4.34, largely due to reduced share count from ongoing share repurchase programs. Despite overall positive trends, the Consumer segment experienced a notable decrease in operating gain due to higher medical costs and adverse selection in Medicare Advantage products, prompting a review of strategy for 2012. The company continued to manage its capital effectively through share repurchases and dividend declarations, with approximately $667.2 million remaining authorized for future repurchases as of June 30, 2011. The company also announced its intention to acquire CareMore Health Group, a senior-focused healthcare delivery program, signaling strategic expansion in the evolving healthcare landscape.

Elevance Health (formerly WellPoint) reported solid financial results for the first quarter of 2011. The company saw an increase in net income to $926.6 million, up 6% year-over-year, leading to a diluted EPS of $2.44, a 24% increase. This growth was driven by improved operating results in the Commercial and Other segments, despite a slight decrease in total operating revenue which fell 1% to $14.65 billion, largely due to the conversion of some large accounts from fully-insured to self-funded plans. The company also demonstrated strong operational cash flow, generating $1.11 billion. Significant share repurchase activity contributed to the EPS growth, with approximately $741.6 million spent on repurchases during the quarter. Elevance Health maintains a strong financial position with $20.7 billion in cash, cash equivalents, and investments.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported its third-quarter 2010 financial results, showing a slight increase in net income to $739.1 million, or $1.84 per diluted share, compared to $730.2 million, or $1.53 per diluted share, in the prior year. This improvement was driven by a one-time charge in the prior year related to intangible asset impairment and increased realized investment gains, partially offset by a decline in operating revenue. Total operating revenue for the quarter decreased by 6% to $14.3 billion, largely due to membership declines in fully-insured plans within the Commercial segment and the conversion of some accounts to self-funded status. The company noted that despite revenue headwinds, disciplined pricing and cost management led to an improved benefit expense ratio and a lower selling, general, and administrative expense ratio. The company also repurchased approximately $3.3 billion of its common stock year-to-date, demonstrating a commitment to returning capital to shareholders. Looking at the nine-month period, net income increased significantly by 17% to $2.3 billion, or $5.52 per diluted share, compared to $2.0 billion, or $4.12 per diluted share, in the prior year. This substantial growth was fueled by a significant reduction in other-than-temporary impairment losses on investments and increased realized investment gains, alongside improved operating performance in the Commercial segment. Total operating revenue for the nine months decreased by 5% to $43.4 billion, reflecting ongoing challenges from membership declines and the sale of the PBM business. The company continues to navigate a complex regulatory environment, including the implications of the newly enacted healthcare reform legislation, while executing on its strategic priorities.

This filing is an amendment to Elevance Health, Inc.'s (formerly WellPoint, Inc.) Form 10-Q for the quarterly period ended June 30, 2010. The primary purpose of this amendment is to furnish XBRL-formatted interactive data files, including consolidated financial statements and notes. It does not introduce new financial information or reflect events subsequent to the original filing date. Therefore, investors should refer to the original 10-Q filing for substantive financial performance analysis and operational updates for the period. As this is an amendment solely for XBRL data, it's crucial for investors to look at the original 10-Q filing from August 3, 2010, which contains the actual financial and operational details. This amendment ensures compliance with SEC interactive data requirements but provides no new insights into the company's business performance, strategic initiatives, or financial condition beyond what was originally reported.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported its financial results for the quarter ending June 30, 2010. The company experienced a decrease in total operating revenue, primarily driven by the conversion of a large municipal account to a self-funded status and the transition of some UniCare members to HCSC. This revenue decline was partially offset by higher premium revenues to cover cost trends and growth in Medicare Advantage and Federal Employee Program membership. Net income saw a modest increase of 4% year-over-year for the quarter, benefiting from improved operating results in the Commercial segment, increased realized investment gains, and lower other-than-temporary impairment losses. Diluted EPS also showed a significant 20% increase, largely attributed to a reduction in outstanding shares due to an active share repurchase program. The company highlighted its strong financial position with substantial cash and investment holdings, though operating cash flow was negatively impacted by a large tax payment related to a prior divestiture.

Elevance Health, Inc. (formerly WellPoint, Inc.) reported solid financial results for the first quarter ended March 31, 2010. The company demonstrated significant year-over-year growth in net income, increasing by 51% to $876.8 million, which translated to a 69% increase in diluted earnings per share (EPS) to $1.96. This improvement was driven by lower benefit expenses, reduced investment impairment charges, and increased realized investment gains, despite a modest 3% decrease in total operating revenue to $14.9 billion, largely attributable to economic pressures affecting fully-insured membership and the divestiture of the PBM business. Key to the EPS growth was a substantial share repurchase program, which reduced the outstanding share count. The company also highlighted its strong financial position, with significant cash and investment balances. Management noted the ongoing impact of healthcare reform legislation, which is expected to bring significant changes to the industry landscape in the coming years, and emphasized continued focus on managing healthcare costs through various programs and strategic initiatives.